Literature DB >> 21232572

The accumulation of neurotoxic proteins, induced by proteasome inhibition, is reverted by trehalose, an enhancer of autophagy, in human neuroblastoma cells.

M J Casarejos1, R M Solano, A Gómez, J Perucho, J G de Yébenes, M A Mena.   

Abstract

Neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, Huntington's disease and others are due to accumulation of abnormal proteins which fold improperly and impair neuronal function. Accumulation of these proteins could be achieved by several mechanisms including mutation, overproduction or impairment of its degradation. Inhibition of the normal protein degradation is produced by blockade of the ubiquitin proteasome system. We have shown that epoxomicin, a proteasome inhibitor, increases the levels of proteins involved in neurodegenerative disorders such as α-synuclein and hyper phosphorylated tau in NB69 human neuroblastoma cells and that such increase correlates with an enhanced rate of cell death. We then investigated whether the stimulation of autophagy, an alternative mechanism for elimination of abnormal proteins, by treatment with trehalose, counteracts the effects of proteasomal blockade. Trehalose, a disaccharide present in many non-mammalian species, known to enhance autophagy, protects cells against various environmental stresses. Treatment with trehalose produced a dose and time-dependent increase in the number of autophagosomes and markers of autophagy in NB69 cells. Trehalose did not change the number of total neither the number of dividing cells in the culture but it completely prevented the necrosis of NB69 induced by epoxomicin. In addition, the treatment with trehalose reverted the accumulation, induced by epoxomicin, of polyubiquitinated proteins, total and phosphorylated tau, p-GSK-3, and α-synuclein, as well as the α-synuclein intracellular aggregates. The effects of trehalose were not mediated through activation of free radical scavenging compounds, like GSH, or mitochondrial proteins, like DJ1, but trehalose reduced the activation of ERK and chaperone HSP-70 induced by epoxomicin. Inhibition of ERK phosphorylation prevented the epoxomicin-induced cell death. Inhibition of autophagy reverted the neuroprotective effects of trehalose in epoxomicin-induced cell death. These results suggest that trehalose is a powerful modifier of abnormal protein accumulation in neurodegenerative diseases.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232572     DOI: 10.1016/j.neuint.2011.01.008

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  44 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

3.  The Involvement of NR2B and tau Protein in MG132-Induced CREB Dephosphorylation.

Authors:  Min Xie; Yuan Li; Shao-Hui Wang; Qun-Tao Yu; Xin Meng; Xiao-Mei Liao
Journal:  J Mol Neurosci       Date:  2017-04-19       Impact factor: 3.444

4.  Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

Authors:  Qing He; James B Koprich; Ying Wang; Wen-bo Yu; Bao-guo Xiao; Jonathan M Brotchie; Jian Wang
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

5.  Identification of GH15 Family Thermophilic Archaeal Trehalases That Function within a Narrow Acidic-pH Range.

Authors:  Masayoshi Sakaguchi; Satoru Shimodaira; Shin-Nosuke Ishida; Miko Amemiya; Shotaro Honda; Yasusato Sugahara; Fumitaka Oyama; Masao Kawakita
Journal:  Appl Environ Microbiol       Date:  2015-05-15       Impact factor: 4.792

Review 6.  Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease.

Authors:  Masoomeh Khalifeh; George E Barreto; Amirhossein Sahebkar
Journal:  Br J Pharmacol       Date:  2019-03-27       Impact factor: 8.739

7.  Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant α-synuclein.

Authors:  Dan-Mei Lan; Feng-Tao Liu; Jian Zhao; Yan Chen; Jian-Jun Wu; Zheng-Tong Ding; Zhen-Yu Yue; Hui-Min Ren; Yu-Ping Jiang; Jian Wang
Journal:  Neurochem Res       Date:  2012-06-17       Impact factor: 3.996

Review 8.  Mechanistic targeting of advanced glycation end-products in age-related diseases.

Authors:  Sheldon Rowan; Eloy Bejarano; Allen Taylor
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-29       Impact factor: 5.187

Review 9.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

10.  Trehalose Alters Subcellular Trafficking and the Metabolism of the Alzheimer-associated Amyloid Precursor Protein.

Authors:  Nguyen T Tien; Ilker Karaca; Irfan Y Tamboli; Jochen Walter
Journal:  J Biol Chem       Date:  2016-03-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.